Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase

Cancer Chemotherapy and Pharmacology

Volumn 38, Issue 1, 1996, Pages 52-58

  Haaz, M C ^a   Fischel, J L ^a   Formento, P ^a   Renee N ^a   Etienne, M C ^a   Milano, G ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Allopurinol; Cisplatin; Dihydropyrimidine dehydrogenase; Dipyridamole; Fluorouracil; Hydroxyurea

Indexed keywords

ALLOPURINOL; CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; DIPYRIDAMOLE; ENZYME INHIBITOR; FLUOROURACIL; HYDROXYUREA; TETRAZOLIUM;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG METABOLISM; DRUG POTENTIATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ALLOPURINOL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA; CELL DIVISION; CISPLATIN; DIHYDROURACIL DEHYDROGENASE (NADP); DIPYRIDAMOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; HYDROXYUREA; OXIDOREDUCTASES; PANCREATIC NEOPLASMS; PLATELET AGGREGATION INHIBITORS; TUMOR CELLS, CULTURED;

EID: 0029913104     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050447     Document Type: Article

References (25)

1. Beck A, Etienne MC, Cheradame S, Fischel JL, Formento P, Renée N, Milano G (1994) A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil. Eur J Cancer 30:1517
2. Cao S, Rustum YM, Spector T (1994) 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 54:1507
3. Carmichael J, De Graff WG, Gazdar AF, Minna JD, Mitchell JB (1987) Evaluation of a tetrazolium-based semi-automated colorimetric assay in assessment of chemosensitivity testing. Cancer Res 47:936
4. Damon LE, Cadman EC (1988) The metabolic basis for combination chemotherapy. Pharmacol Ther 38:73
5. Diasio RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16:215
6. Fleming RA, Milano G, Thyss A, Etienne MC, Renée N, Schneider M, Demard F (1992) Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52:2899
7. Fox RM, Woods RL, Tattersall MH, Piper AA, Sampson D (1981) Allopurinol modulation of fluorouracil toxicity. Cancer Chemother Pharmacol 5:151
8. Gioanni J, Fischel JL, Lambert JC, et al (1988) Two new tumor cell lines derived from squamous cell carcinoma of the tongue: establishment, characterisation and response to cytotoxic treatment. Eur J Cancer Clin Oncol 9:1145
9. Goldstein D, Laszlo J (1986) Interferon therapy in cancer: from imaginon to interferon. Cancer Res 46:4315
10. Grem JL, Fischer PH (1989) Enhancement of 5-fluorouracil's anticancer activity by dipyridamole. Pharmacol Ther 40:349
11. Harris BE, Song R, Soong S, Diasio RB (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50:197
12. Leteurtre F, Croisy A, Perrin F, Carrez D, Bastian G (1990) Pharmacokinetics of 5-fluorouracil in combination with cisplatin: evidence for drug interaction (abstract 1223). Eur J Cancer 26 S:200
13. Eu Z, Zhang R, Diasio RB (1993) Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53:5433
14. Milano G, Fischel JL, Etienne MC, Renée N, Formento P, Thyss A, Gaspard MH, Thill L, Cupissol D (1994) Inhibition of dihydropyrimidine dehydrogenase by α-interferon: experimental data on human tumor cell lines. Cancer Chemother Pharmacol 34:147
15. Milano G, Etienne MC, Dassonville O, Renée K, Formento P, Thyss A, Demard F, Schneider M (1994) Prediction of FU treatment resistance based on tumoral dihydropyrimidine dehydrogenase activity. A clinical study. Proc Am Assoc Cancer Res 35:208
16. Milano G, Fischel JL, Spector T, Etienne MC, Formento P (1995) Enhancement of fluorouracil cytotoxicity by inhibiting dihydropyrimidine dehydrogenase activity with 5-ethynyluracil. Proc Am Assoc Cancer Res (in press)
17. Naguib FNM, Hao SN, El Kouni MH (1994) Potentiation of 5-fluorouracil efficacy by the dihydrouracil dehydrogenase inhibitor, 5-benzyloxybenzyluracil. Cancer Res 54:5166
18. Peters GFJ, Van Groeningen CJ (1991) Clinical relevance of biochemical modulation of 5-fluorouracil. Ann Oncol 2:469
19. Pinedo HM, Peters GFJ (1988) Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6:1653
20. Scanlon KJ, Newman EM, Priest DG (1986) Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 83:8923
21. Schwartz PM, Handschumacher RE (1979) Selective antagonism of 5-fluorouracil cytotoxicitv by 4-hydroxypyrazol pyrimidine (allopurinol) in vitro. Cancer Res 39:3095
22. Tuchman M, Ramnaraine LR, O'Dea RF (1985) Effects of uridine and thymidine on the degradation of 5-fluorouracil, uracil, and thymine by rat liver dihydropyrimidine dehydrogenase. Cancer Res 45:5553
23. Weckbecker G (1991) Biochemical pharmacology and analysis of fluoropyrimidines alone and in combination with modulators. Pharmacol Ther 50:367
24. Yarbro JW (1992) Mechanism of action of hydroxyurea. Semin Oncol 19 [Suppl 9] :1
25. Yokota H, Fernandez-Salguero P, Furuya H, Lin K, McBride W, Podschun B, Schnackerz KD, Gonzalez FJ (1994) cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymidine uraciluria. J Biol Chem 269:23192